# Empagliflozin + Metformin

## Jardiance Duo 12.5/850mg (複方)

| TAH Drug Code      | [OJADU](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OJADU)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Indicated for patients aged 10 years and older with type 2 diabetes who have inadequate blood sugar control with metformin or empagliflozin alone， or those who have been stable on combination therapy with metformin and empagliflozin， as an adjunctive treatment to improve blood sugar control in addition to diet and exercise. Empagliflozin， when used in adults with type 2 diabetes who have cardiovascular disease， can reduce the risk of cardiovascular death. However， the effectiveness of this product in reducing the risk of cardiovascular death in adults with type 2 diabetes and cardiovascular disease has not been established for this product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | Type 2 diabetes mellitus (Immediate-release) MAX: empagliflozin 25 mg/metformin 2000 mg per day. Currently taking metformin: Choose strength that will provide empagliflozin 5 mg PO BID plus similar total daily metformin dose; gradually adjust dose as needed. Currently taking empagliflozin: Choose strength that will provide metformin 500 mg PO BID plus similar total daily empagliflozin dose; gradually adjust dose as needed. Currently taking both components as separate tablets: Choose strength that provides the same daily dose of both components when administered PO BID ; gradually adjust dose as needed. Iodinated contrast imaging procedure in patients with history of liver disease， alcoholism， or heart failure， or patients receiving intraarterial administration of iodinated contrast: Discontinue use at time of or before procedure; evaluate eGFR 48 hours after imaging procedure; restart if renal function stable. Surgery: Withhold treatment for at least 3 days， if possible， prior to major surgery or procedures associated with prolonged fasting. Resume when the patient is clinically stable and has resumed oral intake. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Severe renal impairment (estimated GFR less than 30 mL/min/1.73 m(2))， ESRD， or dialysis. Acute or chronic metabolic acidosis， including diabetic ketoacidosis. History of serious hypersensitivity to empagliflozin， metformin hydrochloride， or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Common: Diarrhea (>5%)， Flatulence (>5%)， Indigestion (>5%)， Nausea， Headache (>5%)， Urinary tract infectious disease (6.9-9.4%)， Female genital infection， Mycotic Serious: Hypotension， Hypovolemia， Diabetic ketoacidosis， Hypoglycemia (1.4-15.6%)， Lactic acidosis， Vitamin B12 level below reference range， Acute renal failure， Pyelonephritis， Sepsis due to urinary tract infection， Necrotizing fasciitis， Perineum                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/empagliflozin-and-metformin-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

